Supernus Pharmaceuticals Inc
Company Profile
Business description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Contact
9715 Key West Avenue
RockvilleMD20850
USAT: +1 301 838-2500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
778
Stocks News & Analysis
stocks
Why great earnings haven't been good enough for AI hardware stocks
stocks
Fair Value increased for Big 4 bank after earnings
stocks
Chart of the Week: Why ASX tech is poised for a comeback
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,382.90 | 7.60 | -0.08% |
| CAC 40 | 8,674.94 | 40.00 | -0.46% |
| DAX 40 | 26,331.07 | 60.35 | -0.23% |
| Dow JONES (US) | 53,770.27 | 21.58 | -0.04% |
| FTSE 100 | 10,833.15 | 11.04 | -0.10% |
| HKSE | 25,440.17 | 212.65 | -0.83% |
| NASDAQ | 26,588.49 | 143.04 | 0.54% |
| Nikkei 225 | 68,411.46 | 887.40 | 1.31% |
| NZX 50 Index | 13,801.90 | 64.24 | 0.47% |
| S&P 500 | 7,748.50 | 20.30 | 0.26% |
| S&P/ASX 200 | 9,181.90 | 11.00 | -0.12% |
| SSE Composite Index | 3,946.68 | 12.58 | 0.32% |